Floatz logo

Elelyso

Type 1 Gaucher Disease

PfizerPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Type 1 Gaucher Disease cohort.

Asset / SponsorPhaseRating
ISOFAGOMINE
Amicus Therapeutics
Phase 2BB
at2101
Amicus Therapeutics
Phase 1CC
AUTOLOGOUS CD34+ CELLS ENCODING .BETA.A-T87Q-GLOBIN GENE
AVROBIO
D

Same molecule, other indications

Elelyso is also rated in:

Gaucher disease type IIIDormant
BB
Indicative ·
69 / 100
View asset →
Gaucher Disease, Type 1Dormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →